Hualan Biological Vaccine, Inc. (301207.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 21Aug 26Aug 31Sep 3Sep 8Sep 11Sep 16Sep 21

Key dataSep 21, 2026

OpenCNY 18.30

From 52W high−34.43%

Volume11.92M

Market capCNY 10.27B

P/E (TTM)56.1x

P/S (TTM)9.2x

Div yield7.62%

Key dataSep 21, 2026

Open

CNY 18.30

From 52W high

−34.43%

Volume

11.92M

Market cap

CNY 10.27B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

56.1x

RSI (14)

55.4

MomentumView details →

1D Return

−4.31%

YTD Return

−1.34%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

56.1x

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

9.2x

P/B (TTM)

1.9x

ProfitabilityView details →

Gross Margin

77.48%

Net Margin

15.56%

EBITDA Margin

27.47%

ROE (TTM)

3.27%

ROA (TTM)

2.74%

Asset Turnover

0.18x

GrowthView details →

Revenue YoY

+7.79%

EPS YoY

−5.55%

FCF YoY

+33.48%

Revenue CAGR 3Y

−12.99%

EPS CAGR 3Y

−29.59%

EBITDA YoY

—

MomentumView details →

1D Return

−4.31%

YTD Return

−1.34%

1Y Return

+6.49%

RSI (14)

55.4

vs 50D SMA

+4.07%

vs 200D SMA

−3.59%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

4.15x

Quick Ratio

3.90x

Div Yield

7.62%

Div Rate

CNY 1.40

Div Growth 1Y

+33.33%

EarningsView details →

EPS (Actual)

−CNY 0.00

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.20B

Net Income (TTM)

187.51M

Op. CF (TTM)

460.78M

Latest newsMore news →

Hualan Biological Vaccine received approval from China's National Medical Products Administration to conduct clinical trials for its novel influenza virus mRNA vaccine.14d ago

Hualan Biological Vaccine Inc. proposed a cash dividend of 1 yuan per 10 shares (tax included) based on a base of 595 million shares, with no bonus shares and no capital reserve conversion.24d ago

Similar companies

维通利001393.SZ 正海磁材300224.SZ 金龙羽002882.SZ 奥海科技002993.SZ 奥普光电002338.SZ 华润材料301090.SZ Find similar companies →

Latest newsMore news →

Hualan Biological Vaccine received approval from China's National Medical Products Administration to conduct clinical trials for its novel influenza virus mRNA vaccine.14d ago Hualan Biological Vaccine Inc. proposed a cash dividend of 1 yuan per 10 shares (tax included) based on a base of 595 million shares, with no bonus shares and no capital reserve conversion.24d ago Hualan Biological's controlling subsidiary Hualan Vaccine is conducting research and development of a novel influenza virus mRNA vaccine.42d ago